other material
confidence high
sentiment positive
materiality 0.80
RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC
Revolution Medicines, Inc.
- Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.
- Median OS of 14.5 months in 2L PDAC; 6-month OS rate 89% (KRAS G12X) and 91% (broader RAS mutant).
- ORR 29% (2L) and 22% (3L+); disease control rate 91% (2L) and 89% (3L+).
- Safety: 98% any grade TRAEs, 29% Grade≥3; no discontinuations; mean dose intensity 92%.
- Data cutoff July 23, 2024; 127 PDAC patients across 160-300 mg daily doses.